[Introduction of a new anticancer drug, novantrone].
Novantrone (mitoxantrone) is a novel anticancer drug, having an anthraquinone structure. This compound was selected from many candidate compounds for purpose to find out a drug having lesser cardiac toxicity than doxorubicin and excellent antitumor activities. In the Japanese clinical trials, Novantrone was proved to be active against breast cancer, malignant lymphoma and acute leukemia. Major side effects observed in the clinical trials were: GI-tract toxicities, and mild alopecia, mild disturbance in the circulatory organs, fever and dermatological toxicities.
Tsukagoshi
S
S
Cancer Chemotherapy Center, Cancer Inst., Tokyo.
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D008813:Mice, Inbred ICR; D008819:Mice, Nude; D008942:Mitoxantrone / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats
D008942:Mitoxantrone